Company Overview of Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase II trials to treat genital herpes infections. It is also developing GEN-004, a Phase II vaccine for the prevention of pneumococcal infections; GEN-001 that is in pre-clinical product candidate for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-...
100 Acorn Park Drive
Cambridge, MA 02140
Founded in 2006
Key Executives for Genocea Biosciences, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $393.6K
Chief Financial Officer and Secretary
Total Annual Compensation: $285.2K
Chief Medical Officer
Total Annual Compensation: $366.1K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2014.
Genocea Biosciences, Inc. Key Developments
Genocea Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 09:20 AM
Mar 25 15
Genocea Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jonathan Poole, Chief Financial Officer.
Genocea Biosciences, Inc. Appoints Michael Higgins as Directors
Feb 27 15
Genocea Biosciences, Inc. announced that Michael Higgins has joined the company's board of directors. Mr. Higgins is an experienced biotechnology executive and is currently entrepreneur-in-residence at Polaris Venture Partners. He previously served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals from 2003 to 2014.
Genocea Biosciences, Inc. Reports Unaudited Financial Results for the Fourth Quarter and Year Ended December 31, 2014
Feb 12 15
Genocea Biosciences, Inc. reported unaudited financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported grant revenue of $0.308 million against $0.020 million a year ago. Loss from operations was $10.926 million against $6.169 million a year ago. Net loss was $11.650 million against $6.346 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $0.66 against $22.50 a year ago.
For the year, the company reported grant revenue of $0.308 million against $0.731 million a year ago. Loss from operations was $33.166 million against $19.925 million a year ago. Net loss was $35.296 million against $20.806 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $2.27 against $75.46 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 20, 2014